A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement

Philip C. Comp, Thomas Voegeli, John W. McCutchen, Vasilios A. Skoutakis, Arthur Trowbridge, William L. Overdyke, Lynn Boynton, Gregory Wise, Hau Kwaan, Ronald W. Geckler, Michael Kalafer, Richard H White, Roger M. Lyons, Paul F. White

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Orgaran (danaparoid sodium injection) is a novel antithrombotic agent. Early studies suggest that this compound may be beneficial in preventing deep vein thrombosis in predisposed patients. This multicenter, randomized, assessor blinded, clinical trial compared subcutaneous danaparoid with warfarin for the prevention of deep vein thrombosis in patients undergoing hip replacement surgery. Bilateral venography was used to detect thrombi. Patients also underwent follow-up examinations 1, 2, and 3 months after discontinuation of the study to determine the after effects of treatment. Nearly 27% of patients who received warfarin and 14.6% of patients who received danaparoid developed deep vein thrombosis, a risk reduction of 46%. The absolute difference in the incidence of deep vein thrombosis was 12.3% in favor of danaparoid. The incidence of venographically documented proximal deep vein thrombosis was 1.5% for danaparoid and 4.1% for warfarin. These results demonstrate that danaparoid is more effective than warfarin in preventing deep vein thrombosis following hip replacement surgery. The preoperative administration of danaparoid does not increase surgical blood loss compared with warfarin.

Original languageEnglish (US)
Pages (from-to)1123-1128
Number of pages6
JournalOrthopedics
Volume21
Issue number10
StatePublished - Oct 1998
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement'. Together they form a unique fingerprint.

  • Cite this

    Comp, P. C., Voegeli, T., McCutchen, J. W., Skoutakis, V. A., Trowbridge, A., Overdyke, W. L., Boynton, L., Wise, G., Kwaan, H., Geckler, R. W., Kalafer, M., White, R. H., Lyons, R. M., & White, P. F. (1998). A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement. Orthopedics, 21(10), 1123-1128.